# EDGAR Filing Document

**Accession Number:** 0001837607
**File Stem:** 0000000000-23-000915
**Filing Date:** 2023-1
**Character Count:** 7765
**Document Hash:** 3c087a9d665e275cb17bab3036412e2d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000915.hdr.sgml**: 20230706

**ACCESSION NUMBER**: 0000000000-23-000915

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230127

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Priveterra Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001837607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 853940478
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 300 SE 2ND STREET
- **STREET 2:** SUITE 600
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** (407) 808-1335

**MAIL ADDRESS:**
- **STREET 1:** 300 SE 2ND STREET
- **STREET 2:** SUITE 600
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

## Text-Extract

```

II
                                                                    Corporate &
Investment Banking

                                                                    Equity
Capital Markets

                                                                    500 West
33rd Street

                                                                    New York,
New York 10001

Strictly Confidential

January 26, 2023

VIA Email: Countrymanv@sec.gov

Vanessa Countryman
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Attention:                 Vanessa Countryman
                           Secretary of the SEC

Re:          Registration Statement on Form S-4 (Registration No. 333-269006)

To whom it may concern:

We write regarding the above-referenced registration statement (the
Registration Statement   ) of Priveterra
Acquisition Corp. (   Priveterra   ) concerning a proposed business combination
(the    Transaction   ) between
Priveterra and AEON Biopharma, Inc. (   AEON   ). As of the date of this
letter, the Registration Statement has not
yet been declared effective.

This letter is to advise you that, effective as of January 26, 2023, our firm
has waived its entitlement to the
payment of the deferred underwriting discount in connection with our role as
underwriter for Priveterra, as
described in the underwriting agreement, dated February 8, 2021, between
Priveterra and Wells Fargo Securities,
LLC. We further confirm that, although our firm does not have any role with
respect to the Transaction, for the
avoidance of doubt, our firm has resigned from, or ceased or refused to act in,
every office, capacity, and
relationship with respect to the Transaction that may be described in the
Registration Statement or otherwise. We
can also confirm that the foregoing waiver of entitlement to the payment of the
deferred underwriting discount
and our resignation, ceasure and refusal to act in, every office, capacity, and
relationship with respect to the
Transaction (even though our firm does not have any role with respect to the
Transaction) is not the result of any
dispute or disagreement with Priveterra, AEON or any matter relating to
Priveterra   s or AEON   s respective
operations, policies, procedures or practices.

We further advise you that neither our firm, any person who controls it (within
the meaning of either Section 15 of
the Securities Act of 1933 (the    Securities Act   )) nor any of its
affiliates (within the meaning of Rule 405 under the
Securities Act) will be responsible for any part of the Registration Statement.

   2023 Wells Fargo & Company. All rights reserved.
Consider whether the engaging entity is sufficiently creditworthy on its own to
support the indemnity and other obligations in the Agreement. In particular, if
the client is a majority-
owned subsidiary of another company, or is controlled by a majority
shareholder, consider obtaining a guarantee from the parent entity or majority
shareholder.
Add bracketed language if there is an additional placement agent for the
Transaction.
 Priveterra Acquisition Corp.
January 26, 2023
Page 2

Please be advised that nothing herein is intended to constitute an
acknowledgment or admission, and we expressly
deny, that we have been or are an underwriter (within the meaning of Section
2(a)(11) of the Securities Act or the
rules and regulations promulgated thereunder) with respect to the Transaction.

Very truly yours,

Wells Fargo Securities, LLC

By:
Lear Beyer
Managing Director

Cc:     Priveterra Acquisition Corp.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![Wells Fargo logo]()

Corporate & Investment Banking
Equity Capital Markets
500 West 33rd Street
New York, New York 10001

Strictly Confidential

January 26, 2023

**VIA Email:** Countrymanv@sec.gov

Vanessa Countryman
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Attention: Vanessa Countryman
Secretary of the SEC

Re: Registration Statement on Form S-4 (Registration No. 333-269006)

To whom it may concern:

We write regarding the above-referenced registration statement (the “Registration Statement”) of Priveterra Acquisition Corp. (“Priveterra”) concerning a proposed business combination (the “Transaction”) between Priveterra and AEON Biopharma, Inc. (“AEON”). As of the date of this letter, the Registration Statement has not yet been declared effective.

This letter is to advise you that, effective as of January 26, 2023, our firm has waived its entitlement to the payment of the deferred underwriting discount in connection with our role as underwriter for Priveterra, as described in the underwriting agreement, dated February 8, 2021, between Priveterra and Wells Fargo Securities, LLC. We further confirm that, although our firm does not have any role with respect to the Transaction, for the avoidance of doubt, our firm has resigned from, or ceased or refused to act in, every office, capacity, and relationship with respect to the Transaction that may be described in the Registration Statement or otherwise. We can also confirm that the foregoing waiver of entitlement to the payment of the deferred underwriting discount and our resignation, ceasure and refusal to act in, every office, capacity, and relationship with respect to the Transaction (even though our firm does not have any role with respect to the Transaction) is not the result of any dispute or disagreement with Priveterra, AEON or any matter relating to Priveterra’s or AEON’s respective operations, policies, procedures or practices.

We further advise you that neither our firm, any person who controls it (within the meaning of either Section 15 of the Securities Act of 1933 (the “Securities Act”)) nor any of its affiliates (within the meaning of Rule 405 under the Securities Act) will be responsible for any part of the Registration Statement.

© 2023 Wells Fargo & Company. All rights reserved.

Consider whether the engaging entity is sufficiently creditworthy on its own to support the indemnity and other obligations in the Agreement. In particular, if the client is a majority-owned subsidiary of another company, or is controlled by a majority shareholder, consider obtaining a guarantee from the parent entity or majority shareholder.

Add bracketed language if there is an additional placement agent for the Transaction.

Priveterra Acquisition Corp.

January 26, 2023

Page 2

Please be advised that nothing herein is intended to constitute an acknowledgment or admission, and we expressly deny, that we have been or are an underwriter (within the meaning of Section 2(a)(11) of the Securities Act or the rules and regulations promulgated thereunder) with respect to the Transaction.

Very truly yours,

Wells Fargo Securities, LLC

By: Lear Beyer
Managing Director

Cc: Priveterra Acquisition Corp.